Express Scripts knocks many newer brands off formulary

Share this article:

Express Scripts, the big PBM, issued its new formulary for 2014, and a list accompanying the formulary shows many recently approved brands won't be covered, reports FiercePharma. Among those being excluded from reimbursement: Pfizer RA drug Xeljanz, Johnson & Johnson psoriasis treatment Stelara, and  GlaxoSmithKline respiratory drug Breo Ellipta. Alternatives are listed beside each.

It's the first time the PBM's preferred formulary designates certain drugs as “not covered,” an Express Scripts spokesman told FiercePharma, adding "Drug choices in some classes are larger than ever, with many products costing more with no additional health benefit."

The co-pay card, a marketing tactic often used by pharma to provide patient assistance for branded drugs, played into Express Scripts's decision, FiercePharma points out.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.